Adverse events experienced by at least 10% of patients by severity

AE, n (%)Total (N = 30)Grade 1Grade 2Grades 3 and 4
Any AE, highest grade experienceda29 (97)2 (7)8 (27)18 (60)
ALT elevation12 (40)5 (17)5 (17)2 (7)
AST elevation12 (40)7 (23)4 (13)1 (3)
Fatigue11 (37)4 (13)5 (17)2 (7)
Thrombocytopenia9 (30)2 (7)2 (7)5 (17)
Nausea6 (20)2 (7)3 (10)1 (3)
Anemia5 (17)2 (7)2 (7)1 (3)
Hypomagnesemia5 (17)5 (17)00
Peripheral edema5 (17)3 (10)2 (7)0
Alkaline phosphatase elevation4 (13)3 (10)1 (3)0
Dysphagia4 (13)3 (10)01 (3)
Dyspnea4 (13)2 (7)2 (7)0
Hypercalcemia4 (13)1 (3)2 (7)1 (3)
Hypokalemia4 (13)3 (10)01 (3)
Hyponatremia4 (13)3 (10)01 (3)
Neutropenia4 (13)1 (3)03 (10)
Vomiting4 (13)4 (13)00
Abdominal pain3 (10)1 (3)2 (7)0
Anorexia3 (10)1 (3)2 (7)0
Asthenia3 (10)1 (3)1 (3)1 (3)
Constipation3 (10)3 (10)00
Creatinine elevated3 (10)2 (7)1 (3)0
Diarrhea3 (10)3 (10)00
Upper respiratory tract infection3 (10)1 (3)2 (7)0
Urinary tract infection3 (10)1 (3)2 (7)0

Abbreviations: AE adverse event, AST aspartate transaminase, ALT alanine transaminase

aIncludes one patient who died of acute respiratory failure (Grade 5 AE) unrelated to the study medication while on trial